Islamabad (HRNW) — Under the effective leadership of Federal Minister for National Health Syed Mustafa Kamal, Pakistan is increasingly becoming a hub for global investment. On the very first day of the Pakistan–China Pharmaceutical B2B Conference, agreements worth $44.4 million were signed, demonstrating growing international confidence in ongoing health-sector reforms and investor-friendly policies. This development marks a significant milestone not only for the pharmaceutical industry but also for Pakistan’s economy, employment, and China–Pakistan economic cooperation.
On the occasion, Prime Minister of Pakistan Shehbaz Sharif praised Federal Health Minister Syed Mustafa Kamal for his effective leadership, ongoing reforms in the health sector, and efforts to promote international investment in Pakistan. Officials say these agreements will help improve medicine availability, boost local production, facilitate technology transfer and enhance export capacity.
Economic and employment impact
Experts say this investment will lead to new modern production lines in the pharma sector, reduce costs and create new job opportunities. At the same time, improved supply of quality medicines is expected to have positive effects on public health outcomes.
Human rights and policy angle
HRNW stresses that alongside promoting investment, it is essential to ensure affordable medicine prices, quality control, transparent tendering and public access, so that economic gains also safeguard citizens’ right to health.
Important Note:
This report is based on official statements and initial information. Final details of the agreements, implementation timelines and related regulations will be issued through official updates from the relevant authorities.
